文章摘要
王小剑,李玲,罗驰,谢先红,孟莉.生长抑素辅助治疗重症急性胰腺炎患者的有效性及不良反应分析[J].中国临床保健杂志,2020,23(3):365-368.
生长抑素辅助治疗重症急性胰腺炎患者的有效性及不良反应分析
The efficacy and adverse reactions of somatostatin in the adjuvant treatment of severe acute pancreatitis
投稿时间:2019-12-10  
DOI:10.3969/J.issn.1672-6790.2020.03.019
中文关键词: 胰腺炎,急性坏死性  生长抑素  药物疗法,联合  药物相关性副作用和不良反应
英文关键词: Pancreatitis,acute necrotizing  Somatostatin  Drug therapy,combination  Drug-related side effects and adverse reactions 〖FL
基金项目:四川省教育厅科研基地项目(SWFZ18-38)
作者单位E-mail
王小剑 四川成都市第七人民医院急诊科,610021 wy89761@163.com 
李玲 四川成都市第七人民医院急诊科,610021  
罗驰 四川成都市第七人民医院急诊科,610021  
谢先红 四川成都市第七人民医院急诊科,610021  
孟莉 四川成都市第七人民医院急诊科,610021  
摘要点击次数: 180
全文下载次数: 180
中文摘要:
      目的 探讨生长抑素辅助治疗重症急性胰腺炎患者的有效性及不良反应情况。方法 选取我院2016年3月至2018年10月收治的81例重症急性胰腺炎患者作为研究对象,将其按照随机数字表法分为两组,对照组(n=40)采用泮托拉唑钠治疗,观察组(n=41)在此基础上给予生长抑素治疗,对比两组患者治疗效果差异。结果 观察组总有效率为95.12%,明显高于对照组75.00%(P<0.05);观察组各项症状体征缓解时间均明显短于对照组(P<0.05);两组患者治疗前白细胞介素-8(IL-8)、肿瘤坏死因子-α(TNF-α)、超敏C反应蛋白(hs-CRP)差异无统计学意义(P>0.05),治疗后两组炎性因子水平均明显改善,其中观察组改善程度更明显(P<0.05);观察组不良反应发生率为4.88%,明显低于对照组(20.00%),P<0.05。结论 生长抑素辅助治疗重症急性胰腺炎患者的有效性高,不良反应少。
英文摘要:
      Objective To investigate the efficacy and adverse reactions of somatostatin in the adjuvant treatment of severe acute pancreatitis.Methods 81 patients with severe acute pancreatitis admitted to our hospital from March 2016 to October 2018 were selected as the research objects.They were randomly divided into two groups according to the random number table method.The control group (n=40) was treated with pantoprazole sodium,and the observation group (n=41) was treated with somatostatin on this basis.The therapeutic effects of the two groups were compared.Results The total effective rate of the observation group was 95.12%,which was significantly higher than 75.00% of the control group (P<0.05).The remission time of symptoms and signs of the observation group was significantly shorter than that of the control group (P<0.05).The differences of serum IL-8 (IL-8),TNF-alpha (TNF-a),hs-CRP (high sensitivity C-reactive protein) between the two groups before treatment were significant.There was no statistical significance (P>0.05).After treatment,the levels of inflammatory factors in both groups were significantly improved,especially in the observation group (P<0.05).The incidence of adverse reactions in the observation group was 4.88%,which was significantly lower than that (20.00%) in the control group (P<0.05).Conclusion Somatostatin is an effective adjuvant therapy for severe acute pancreatitis with few adverse reactions.
查看全文     
关闭
分享按钮